GlobalData,
the industry analysis specialist, has released its new report, “Urinary
Incontinence (UI) Therapeutics - Pipeline Assessment and Market
Forecasts to 2018”. The report is an essential source of information and
analysis on the global UI therapeutics market. The report identifies
the key trends shaping and driving the global UI therapeutics market.
The report also provides insights on the prevalent competitive landscape
and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global UI
therapeutics sector. This report is built using data and information
sourced from proprietary databases, primary and secondary research and
in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis valued the Urinary Incontinence (UI) market to be worth $2.6 billion in 2010. Pfizer, Inc., Astellas Pharma and Allergan Inc. are the key players operating in this market. Some of the key brands in the UI therapeutics market include Detrol, Botox, Vesicare, Sanctura, Ditropan and others. The UI therapeutics market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.0% for the next eight years to reach $4.5 billion by 2018.
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
Scope
The report provides information on the key drivers and challenges of the UI therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) UI therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as transient receptor potential vanilloid (TRPV) antagonists, beta 3 adrenergic receptor antagonists and others.
- Analysis of the current and future competition in the global UI therapeutics market. Key market players covered are Allergan Inc., Astellas Pharma, Antares Pharma, Teva Pharmaceutical Company limited and others.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the UI therapeutics market.
- Analysis of key recent licensing and partnership agreements in UI therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline "Wolverine Power Supply Cooperativeproducts and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global UI therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global UI therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global UI therapeutics market landscape? – Identify, understand and capitalize.
For more information, please visit:
http://www.aarkstore.com/reports/Urinary-Incontinence-UI-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018-160117.html
Or email us at press@aarkstore.com or call +919272852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
GlobalData’s analysis valued the Urinary Incontinence (UI) market to be worth $2.6 billion in 2010. Pfizer, Inc., Astellas Pharma and Allergan Inc. are the key players operating in this market. Some of the key brands in the UI therapeutics market include Detrol, Botox, Vesicare, Sanctura, Ditropan and others. The UI therapeutics market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.0% for the next eight years to reach $4.5 billion by 2018.
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
Scope
The report provides information on the key drivers and challenges of the UI therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) UI therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as transient receptor potential vanilloid (TRPV) antagonists, beta 3 adrenergic receptor antagonists and others.
- Analysis of the current and future competition in the global UI therapeutics market. Key market players covered are Allergan Inc., Astellas Pharma, Antares Pharma, Teva Pharmaceutical Company limited and others.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the UI therapeutics market.
- Analysis of key recent licensing and partnership agreements in UI therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline "Wolverine Power Supply Cooperativeproducts and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global UI therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global UI therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global UI therapeutics market landscape? – Identify, understand and capitalize.
For more information, please visit:
http://www.aarkstore.com/reports/Urinary-Incontinence-UI-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018-160117.html
Or email us at press@aarkstore.com or call +919272852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
Thanks for posting this! I'm trying to find information on Incontinent and this has definitely helped me in this process.
ReplyDelete